CytomX Therapeutics
CytomX Therapeutics' revenue fell 44.8% to $76 million in fiscal 2025. Its operating margin was −29.4%, down from 18.1% a year earlier. Free cash flow was −$76 million. The diluted share count rose 62.8%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What CytomX Therapeutics does
CytomX Therapeutics is a clinical-stage company focused on cancer drugs, meaning its medicines are still being tested in people. Its PROBODY technology puts a mask on an antibody-based drug. The mask is meant to come off only inside a tumor, where enzymes called proteases remove it, so the drug targets the tumor more and healthy tissue less.
It is testing two drugs in early, Phase 1 trials. The most advanced, Varseta-M, is an antibody-drug conjugate, which is an antibody that carries a cell-killing drug, aimed at a protein called EpCAM, first for colorectal cancer. The second is CX-801. It also has earlier programs and applies its technology to other drug types, including T-cell engagers and cytokines.
CytomX has had no revenue from product sales. It says it aims to move its drugs to later stages and eventually build a commercial company. It uses outside manufacturers in countries including in Europe and China.
Its biggest risks, as it describes them
- It has no product sales, has lost money, and may never be profitable.
- Clinical development is long and costly, and early results may not predict later ones.
- Its drugs may cause side effects that delay or prevent approval.
- Early data it releases may change as more patient information comes in.
- Problems enrolling patients could delay trials and approvals.
Income statement
CytomX Therapeutics lost money in fiscal 2025: a net loss of $17 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 266 | 194 | 175 | 102 | 137 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 4.0x | 1.6x | 1.2x | 1.2x | 3.1x |
| Quick ratio | 4.0x | 1.6x | 1.2x | 1.2x | 3.1x |
Cash flow
Projections
Project CytomX Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of CytomX Therapeutics reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | 34.2% | −26.2% | −144.3% |
| Altman Z'' | −11.22 | −16.14 | −10.12 |
| Accruals ratio | 24.0% | 73.3% | 42.8% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Pass | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Pass | Fail |
| Cash from operations exceeds net income | Fail | Fail | Fail |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Pass | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Pass | Pass | Fail |
| F-score | — | — | — |
Compare
Put CytomX Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| CytomX Therapeutics | FY25 | −44.8% | −29.4% | −99.5% | — | — | — | |
| Recursion Pharmaceuticals | FY25 | 26.9% | −867.9% | −506.5% | −117.2% | — | 4 | Compare |
| MeiraGTx | FY25 | 144.6% | −130.2% | −61.7% | — | — | 3 | Compare |
| Vir Biotechnology | FY25 | −7.6% | −699.2% | −578.5% | — | — | — | Compare |
| 4D Molecular Therapeutics | FY25 | 230,194.6% | −187.2% | −128.7% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 15 | 72 | 60 | 27 | 68 | 37 | 53 | 101 | 138 | 76 |
| Revenue growth | 95.1% | 376.1% | −16.9% | −54.8% | 154.4% | −45.5% | 42.5% | 90.4% | 36.5% | −44.8% |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Research and development | 55 | 92 | 104 | 132 | 113 | 114 | 112 | 78 | 83 | 69 |
| Operating income | −60 | −46 | −78 | −142 | −80 | −116 | −101 | −6 | 25 | −22 |
| Net income | −59 | −43 | −85 | −133 | −65 | −116 | −99 | −1 | 32 | −17 |
| Diluted EPS (US$) | −1.63 | −1.16 | — | −2.93 | −1.40 | −1.81 | −1.51 | −0.01 | 0.38 | −0.15 |
| Diluted shares (millions) | 36 | 37 | 42 | 45 | 46 | 64 | 66 | 74 | 85 | 138 |
| Cash flow | ||||||||||
| Cash from operations | −2 | 170 | −76 | −140 | 5 | −119 | −111 | −56 | −86 | −76 |
| Capital expenditure | 2 | 2 | 4 | 4 | 2 | 2 | 2 | 1 | 0 | 0 |
| Free cash flow | −4 | 169 | −79 | −144 | 3 | −121 | −113 | −57 | −87 | −76 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 10 | 11 | 17 | 19 | 15 | 13 | 13 | 9 | 8 | 6 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 182 | 374 | 436 | 279 | 256 | 266 | 194 | 175 | 102 | 137 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — | — | — |
| Total assets | 199 | 398 | 457 | 341 | 359 | 339 | 261 | 202 | 120 | 152 |
| Total liabilities | 121 | 328 | 326 | 290 | 366 | 340 | 347 | 249 | 121 | 53 |
| Shareholders' equity | 78 | 70 | 136 | 26 | −8 | −0 | −86 | −47 | −0 | 99 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating margin | −396.1% | −64.6% | −130.9% | −525.9% | −117.7% | −311.0% | −190.6% | −6.4% | 18.1% | −29.4% |
| Net margin | −391.5% | −60.2% | −142.2% | −493.7% | −94.7% | −310.5% | −186.8% | −0.6% | 23.1% | −22.8% |
| Free cash flow margin | −28.0% | 235.7% | −133.3% | −535.2% | 4.3% | −323.3% | −211.7% | −56.2% | −62.7% | −99.5% |
| Rule of 40 (growth + FCF margin) | 67.1% | 611.8% | −150.2% | −590.0% | 158.7% | −368.8% | −169.2% | 34.2% | −26.2% | −144.3% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | −57.6% | −58.1% | −82.2% | −164.7% | — | — | — | — | — | −35.2% |
| Return on assets | −29.7% | −14.4% | −19.8% | −33.3% | −18.5% | −33.2% | −33.1% | −0.2% | 19.8% | −12.8% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |